Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

I-tech

57,40 SEK

+0,70 %

Mindre end 1K følgere

ITECH

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+0,70 %
-20,94 %
-35,94 %
-44,00 %
-1,03 %
+15,26 %
+1,06 %
-14,33 %
+132,72 %

I-tech operates in marine technology. The company conducts research and development of substances that inhibit marine fouling on ship hulls. In addition, the products can be used for various marine installations in fish farming and offshore. Customers are found in the marine paint industry and among other players in the shipping industry. I-Tech was founded in 2000 and has its headquarters in Mölndal.

Læs mere
Markedsværdi
688,67 mio. SEK
Aktieomsætning
653,95 t SEK
Omsætning
179,45 mio.
EBIT %
25,35 %
P/E
17,39
Udbytteafkast, %
1,74 %
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
5.2
2026

Årsrapport '25

7.5
2026

Delårsrapport Q1'26

21.8
2026

Delårsrapport Q2'26

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Eksterne analyser27.11.2025, 09.39

I-tech: Proposed non-renewal of Selektope in the EU - ABG

* European Commission drafts proposal for non-renewal of Selektope* Limited impact on near-term estimates, EU ~2% of total sales* Voting expected to occur some time in H1'26, final decision in mid-26European Commission drafts proposal for non-renewal...

I-tech
Selskabsmeddelelse27.11.2025, 07.45

I-Tech strongly rejects the European Commission’s proposed non-renewal of Medetomidine under the EU Biocidal Products Regulation (BPR)

I-tech
Pressemeddelelse24.11.2025, 09.00

I-Tech and Havey sign MoU to collaborate on the development of next-generation antifouling materials

I-tech

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse18.11.2025, 09.00

I-Tech's Nomination Committee appointed

I-tech
Pressemeddelelse21.10.2025, 08.25

Redeye: I-Tech (Q3 Review) - Forecasts Trimmed, Long-Term View Unchanged

I-tech
Eksterne analyser20.10.2025, 07.17

I-tech: Customer slowdown tempers growth - ABG

* Q3 softer due to sizeable customer trimming '25 volumes* '25e-'27e sales cut by 11-6% and '26e-'27e EBIT by 12-8%* We believe I-Tech remains strongly positioned to grow market shareGrowth dampened by customer volume cutsI-Tech reported weaker than ...

I-tech
Eksterne analyser17.10.2025, 07.05

I-tech: Q3 impacted by weaker market conditions - ABG

Sales -18% vs. ABGSCe, EBIT SEK 11m vs. ABGSCe 16m* Newbuild market down 50% y-o-y, affecting growth* Sizeable customer has reduced planned volumes for '25Q3 resultsQ3 sales came in lower than expected at SEK 41m (-18% vs. ABGSCe 50m). The company writes...

I-tech
Selskabsmeddelelse17.10.2025, 06.00

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the third quarter 2025

I-tech
Eksterne analyser7.10.2025, 07.09

I-tech: Sales recovery expected in Q3 - ABG

* Report out on 17 October* Q3e sales of SEK 50m, +23% y-o-y, EBIT SEK 16m (9m)* Q3 rebound expected after Q2 dip Q3 expectations We estimate Q3 sales of SEK 50m, +23% y-o-y (+35% organic, -12% FX). We expect Q3 to demonstrate that Q2 was a temporary...

I-tech
Pressemeddelelse25.8.2025, 09.24

Redeye: I-Tech - Q2 Review – Temporary Slowdown

I-tech
Eksterne analyser25.8.2025, 05.28

I-tech: A pause, not a stop - ABG

* Weaker Q2 due to natural quarterly variations* Cut '25e-'27e EBIT by 12-13%* Demand intact, rebound expected in Q3Growth halted, but we expect a rebound in Q3I-Tech reported weaker Q2 sales of SEK 32m (-39% vs. ABGSCe, -26% y-o-y) and EBIT of SEK 5m...

I-tech
Eksterne analyser22.8.2025, 07.42

I-tech: Big Q2 miss halts sales growth - ABG

* Sales -39% vs. ABGSCe, EBIT SEK 5m vs. ABGSCe 16m * Weak Q2 due to inventory build-up following strong Q4/Q1* Gross margin continues to improve (59% vs. ABGSCe 56%) Weaker Q2 than expected Sales came in lower than expected at SEK 32m (-39% vs. ABGSCe...

I-tech
Selskabsmeddelelse22.8.2025, 06.00

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the second quarter 2025

I-tech
Eksterne analyser11.8.2025, 07.08

I-Tech: Resilient growth ahead despite FX headwinds - ABG

Q2e sales of SEK 52m, 22% y-o-y, adj. EBIT of SEK 17m (12m) FX headwinds, but we expect customer growth to remain solid Minor estimate changes ahead of report Q2 expectations We anticipate a negative FX impact in Q2 from the depreciation of the USD/SEK...

I-tech
Selskabsmeddelelse13.6.2025, 13.30

I-Tech announces outcome of warrant exercise

I-tech
Eksterne analyser23.5.2025, 12.27

I-tech: Announce one year extension of Selektope approval - ABG

Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m FY'25 guidance maintained, as expected Consensus to lower '25e EBITDA by ~10% on Q1 miss Q1 revenues 3% below, EBIT DKK -1m vs. ABGSCe DKK 11m North Media's Q1 revenues of DKK 311m came in 3% below...

I-tech
Pressemeddelelse23.5.2025, 11.40

I-Tech announces a one year extension of the current EU Approval for Selektope (Medetomidine)

I-tech
Selskabsmeddelelse15.5.2025, 15.30

Report from the Annual General Meeting 2025 of I-tech AB (publ)

I-tech
Pressemeddelelse12.5.2025, 08.23

Redeye: I-Tech Q1 Review - Upward Adjustments

I-tech
Eksterne analyser9.5.2025, 05.25

I-tech: The winning formula continues to unfold - ABG

Strong Q1 sales of SEK 57m, +49% y-o-y '25e-'27e sales and EBIT up 5-6% and 9%, respectively Growth in market share should overshadow market uncertainty The growth journey continues I-Tech reported strong sales of SEK 57m (+9% vs. ABGSCe, +49% y-o-y)...

I-tech
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.